



OCT 21 2004

"Express Mail" mailing number: ER 985998099 US
Date of Deposit: October 21, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Cathi H. Turner
Cathi H. Turner

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thakker et al.

Group Art Unit: 1617

Serial No.: 09/974,519

Examiner: Webman, E. J.

Filed: October 20, 2001

Docket No.: 421/32/2

Confirmation No.: 7285

For: COMPOSITIONS AND METHODS FOR ENHANCING PARACELLULAR PERMEABILITY ACROSS EPITHELIAL AND ENDOTHELIAL BARRIERS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

10/26/2004 AWONDAF1 00000089 500426 09974519

02 FC:1806 180.00 DA

Serial No.: 09/974,519

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a Final Action or the Notice of Allowance.

Early passage of the subject application to issue is earnestly solicited.

The Commissioner is hereby authorized to charge the \$180.00 fee for the filing of this Information Disclosure Statement, and any other fees associated with the filing of this document, to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date:

10/21/2004

By:



Arles A. Taylor, Jr.
Registration No. 39,395

421/32/2 AAT/CPP/cht

Enclosures

Customer No: 25297



FORM 1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant				Attorney Docket No.: 421/32/2		Serial No.: 09/974,519	
				Applicant(s): Thakker et al.			
				Filing Date: October 20, 2001		Group: 1619	
U.S. PATENT DOCUMENTS							
Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No	
	1.	WO 02/11666	02/14/2002		Kozak et al.	Yes	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	2.	European Search Report for Application No. 01 986 603.7 – 1223, dated May 7, 2004.					
	3.	Berkovic, et al., <i>Hexadecylphosphocholine Inhibits Phosphatidylinositol and Phosphatidylcholine Phospholipase C in Human Leukemia Cells</i> , <u>Journal of Experimental Therapeutics & Oncology</u> , 1, pp. 302-311 (1996).					
	4.	Cereijido, et al., <i>The Making of a Tight Junction</i> , <u>Journal of Cell Science</u> , Supplement 17, pp. 127-132 (1993).					
	5.	Grunicke, et al., <i>Inhibition of Phospholipase C and Protein Kinase C by Alkylphosphocholines</i> , <u>Drugs of Today</u> , 34, pp. 3-14 (1998).					
	6.	Hashimoto, et al., <i>Effects of B-Lactoglobulin on the Tight-junctional Stability of Caco-2-SF Monolayer</i> , 62(9), pp. 1819-1821 (1998).					
	7.	Hilgard et al., <i>Inhibitors of Signal Transduction: The Alkylphosphocholines</i> , <u>Drug News Perspect</u> , 12(2), pp. 69-72 (March 1999).					
	8.	Lowenstein and Pawelczyk, <i>Inhibition of Phospholipase Co by Hexadecylphosphorylcholine and Lysophospholipids with Antitumor Activity</i> , <u>Biochemical Pharmacology</u> , 45(2), pp. 493-497 (1993).					
	9.	Liu et al., <i>Dodecylphosphocholine-Mediated Enhancement of Paracellular Permeability and Cytotoxicity in Caco-2 Cell Monolayers</i> , <u>Journal of Pharmaceutical Sciences</u> , 88(11), pp. 1161-1168, (November 1999).					

EXAMINER _____

DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM 1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant				Attorney Docket No.: 421/32/2		Serial No.: 09/974,519	
				Applicant(s): Thakker et al.			
				Filing Date: October 20, 2001		Group: 1619	
U.S. PATENT DOCUMENTS							
Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No	
	1.	WO 02/11666	02/14/2002		Kozak et al.	Yes	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	2.	European Search Report for Application No. 01 986 603.7 – 1223, dated May 7, 2004.					
	3.	Berkovic, et al., <i>Hexadecylphosphocholine Inhibits Phosphatidylinositol and Phosphatidylcholine Phospholipase C in Human Leukemia Cells</i> , <u>Journal of Experimental Therapeutics & Oncology</u> , 1, pp. 302-311 (1996).					
	4.	Cereijido, et al., <i>The Making of a Tight Junction</i> , <u>Journal of Cell Science</u> , Supplement 17, pp. 127-132 (1993).					
	5.	Grunicke, et al., <i>Inhibition of Phospholipase C and Protein Kinase C by Alkylphosphocholines</i> , <u>Drugs of Today</u> , 34, pp. 3-14 (1998).					
	6.	Hashimoto, et al., <i>Effects of B-Lactoglobulin on the Tight-junctional Stability of Caco-2-SF Monolayer</i> , 62(9), pp. 1819-1821 (1998).					
	7.	Hilgard et al., <i>Inhibitors of Signal Transduction: The Alkylphosphocholines</i> , <u>Drug News Perspect</u> , 12(2), pp. 69-72 (March 1999).					
	8.	Lowenstein and Pawelczyk, <i>Inhibition of Phospholipase C by Hexadecylphosphorylcholine and Lysophospholipids with Antitumor Activity</i> , <u>Biochemical Pharmacology</u> , 45(2), pp. 493-497 (1993).					
	9.	Liu et al., <i>Dodecylphosphocholine-Mediated Enhancement of Paracellular Permeability and Cytotoxicity in Caco-2 Cell Monolayers</i> , <u>Journal of Pharmaceutical Sciences</u> , 88(11), pp. 1161-1168, (November 1999).					

EXAMINER _____

DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.